Pramlintide
From PeptideSciences101, the open peptide reference. · Last updated: October 7, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
FDA-approved for type 1 and type 2 diabetes as adjunct to insulin.
Reported benefits
Reduced post-meal glucose, weight loss, appetite control
Protocols & dosing
Typical dosage: 60-120 mcg (with meals).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Pramlintide is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.
| Country | Status |
|---|---|
| United States | Research use only |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Nausea, hypoglycemia risk with insulin
References
No external sources have been catalogued for this article yet.
Related peptides
- AOD-9604 — Fat loss, metabolic enhancement
- CagriSema — Combination therapy
- Dulaglutide — Weekly GLP-1 (Trulicity)
- Fragment 176-191 — HGH fragment for fat loss
- Leptin — Satiety hormone
- Liraglutide — FDA-approved GLP-1 for weight loss
Categories: Weight Management & Metabolic